Prevalence of inapropriate LDL cholesterol levels in patients with coronary disease and/or type 2 diabetes;Prevalencia de colesterol LDL inadecuado en pacientes con enfermedad coronaria y/o diabetes mellitus tipo 2

Revista Clinica Espanola

Volumn 212, Issue 10, 2012, Pages 475-481

  Perez De Isla L ^a   Saltijeral Cerezo, A ^b   Vitale, G ^c   Gonzalez Timon B ^c   Torres Do Rego, A ^d   Alvarez Sala Walther L A ^d  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b España Electronic address: juanmartinnav hotmailcom   (Spain)

^c Medical affairs Merck sharp and Dohme ltd   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cardiovascular risk control; Cardiovascular risk factors; Hypercholesterolaemia; Metabolic syndrome

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CONCENTRATION (PARAMETERS); CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIET THERAPY; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SPAIN; TREATMENT OUTCOME;

EID: 84868513917     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2012.07.003     Document Type: Article

References (25)

1. S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avenzum, and F. Lanas Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
2. C. Baigent, A. Keech, P.M. Kearney, L. BlacKwell, G. Buck, and C. Pollicino Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
3. J.M.S. Lee, and R.P. Choudhury Prospects for atherosclerosis regression through increase in high density lipoprotein and other emerging therapeutic targets Heart 93 2007 559 564
4. J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, and J.H. Stein Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
5. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
6. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, D.B. Hunninghake Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
7. J.R. González-Juanatey, J. Millán, E. Alegría, C. Guijarro, J.V. Lozano, and G.C. Vitale Prevalencia y características de las anomalías lipídicas de pacientes tratados con estatinas en prevención primaria y secundaria en España. Estudio DYSIS-España Rev Esp Cardiol 64 2011 286 294
8. P.M.M. Zimmet, K.G. Alberti, and M. Serrano Ríos Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: fundamento y resultados Rev Esp Cardiol 58 2005 1371 1376
9. J.R. González-Juanatey, L. Grigorian, M.A. Juiz, M. Sánchez, E. Rodríguez, and J. Dopico Impacto pronóstico de la localización de la enfermedad aterosclerosa previa en pacientes diabéticos. Estudio Barbanza-diabetes Rev Esp Cardiol 61 2008 1168 1177
10. J.F. Ascaso, J. Millán, R. Mateo-Gallego, A. Ruiz, M. Suarez-Tembra, R.M. Borrallo On behalf of the Hypertriglyceridemia Registry of the Spanish Arteriosclerosis Society Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population Eur J Intern Med 22 2011 177 181
11. M. Grau, R. Elosua, A. Cabrera de León, M.J. Guembe, J.M. Baena-Díez, and T. Vega Alonso Factores de riesgo cardiovascular en España en la primera década del siglo xxi: análisis agrupado con datos individuales de 11 estudios de base poblacional: el estudio DARIOS Rev Esp Cardiol 64 2011 295 304
12. L.A. Álvarez-Sala Walther, C. Suárez Fernández, M. Camafort Babkowski Grupo de Trabajo de Riesgo Vascular de la SEMI 2010: ¿Qué ha habido de nuevo en riesgo vascular? Rev Clin Esp 211 2011 410 422
13. M.A. Moreno-Palanco, P. Ibáñez-Sanz, C. Ciria-de Pablo, A. Pizarro-Portillo, F. Rodríguez-Salvanés, and C. Suárez-Fernández Impacto de un tratamiento integral e intensivo de factores de riesgo sobre la mortalidad cardiovascular en prevención secundaria: estudio MIRVAS Rev Esp Cardiol 64 2011 179 185
14. M.J. Stampfer, F.M. Sacks, S. Salvini, W.C. Willett, and C.H. Hennekens A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction N Engl J Med 325 1991 373 381
15. G. Assmann, and H. Schulte Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study Am J Cardiol 70 1992 733 737
16. G. Assmann, H. Schulte, A. von Eckardstein, Y. Huang High-density lipoprotein cholesterol as a predictor of coronary heart disease risk The PROCAM experience and pathophysiological implications for reverse cholesterol transport Atherosclerosis 124 Suppl 1996 S11 S20
17. F.D. de Rojas, T. de Frutos, A. Ponte, J.M. Chacón, G.C. Vitale PRINCEPS Investigators Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study Prev Cardiol 12 2009 65 71
18. S. Tranche Iparraguirre, I. López Rodríguez, J.M. Mostaza Prieto, B. Soler López, M.T. Mantilla Morató, and M. Taboada Taboada Control of coronary risk factors in secondary prevention: PRESENAP study Med Clin (Barc) 127 2006 765 769
19. V. Barrios, C. Escobar, N. Murga, and J.J. Quijano Clinical profile and management of patients with chronic ischemic heart disease according to age in the population daily attended by cardiologists in Spain The ELDERCIC study Eur J Intern Med 21 2010 180 184
20. A. Pérez, C. González Blanco, M.Á. Hernández-Presa, and J. Chaves Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease Endocrinol Nutr 58 2011 283 290
21. B. Lahoz-Rallo, M. Blanco-González, I. Casas-Ciria, J.A. Marín-Andrade, J.C. Méndez-Segovia, and G. Moratalla- Rodríguez Cardiovascular disease risk in subjects with type 2 diabetes mellitus in a population in southern Spain Diabetes Res Clin Pract 76 2007 436 444
22. J.M. Mostaza-Prieto, L. Martín-Jadraque, I. López, S. Tranche, C. Lahoz, and M. Taboada Evidence-based cardiovascular therapies and achievement of therapeutic goals in diabetic patients with coronary heart disease attended in primary care Am Heart J 152 2006 1064 1070
23. M. León Latre, E.M. Andrés, A. Cordero, I. Pascual, C. Vispe, and M. Laclaustra Relación entre el síndrome metabólico y la mortalidad cardiopatía isquémica en España Rev Esp Cardiol 62 2009 1469 1472
24. E.H. Chung, P.J. Curran, S. Sivasankaran, M.S. Chauhan, D.E. Gossman, and C.T. Pyne Prevalence of metabolic syndrome in patients ≤ 45 years of age with acute myocardial infarction having percutaneous coronary intervention Am J Cardiol 100 2007 1052 1055
25. A. Mente, S. Yusuf, S. Islam, M.J. McQueen, S. Tanomsup, and C.L. Onen Metabolic syndrome and risk of acute myocardial infarction. A case-control study of 26,903 subjects from 52 countries J Am Coll Cardiol 55 2010 2390 2398